Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
McKinsey
Argus Health
Colorcon
AstraZeneca
Mallinckrodt
Fish and Richardson
Express Scripts
Covington

Generated: November 14, 2018

DrugPatentWatch Database Preview

Actavis Labs Company Profile

« Back to Dashboard

What is the competitive landscape for ACTAVIS LABS, and what generic and branded alternatives to ACTAVIS LABS drugs are available?

ACTAVIS LABS has one hundred and seven approved drugs.

There are three tentative approvals on ACTAVIS LABS drugs.

Summary for Actavis Labs
US Patents:0
Tradenames:82
Ingredients:74
NDAs:107

Drugs and US Patents for Actavis Labs

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actavis Labs Fl Inc HYDROMORPHONE HYDROCHLORIDE hydromorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 202144-004 Jun 30, 2016 AB RX No No ➤ Sign Up ➤ Sign Up
Actavis Labs Fl Inc TAMOXIFEN CITRATE tamoxifen citrate TABLET;ORAL 070929-002 Feb 20, 2003 AB RX No No ➤ Sign Up ➤ Sign Up
Actavis Labs Fl Inc DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE dutasteride; tamsulosin hydrochloride CAPSULE;ORAL 202975-001 Nov 20, 2015 AB RX No No ➤ Sign Up ➤ Sign Up
Actavis Labs Fl Inc METAXALONE metaxalone TABLET;ORAL 203695-001 Jun 15, 2017 AB RX No No ➤ Sign Up ➤ Sign Up
Actavis Labs Fl Inc CLARITHROMYCIN clarithromycin TABLET, EXTENDED RELEASE;ORAL 065145-001 Jun 24, 2004 AB RX No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Actavis Labs

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Actavis Labs Ut Inc EMLA lidocaine; prilocaine CREAM;TOPICAL 019941-001 Dec 30, 1992 4,529,601 ➤ Sign Up
Actavis Labs Ut Inc LOXITANE loxapine succinate CAPSULE;ORAL 017525-001 Approved Prior to Jan 1, 1982 3,546,226 ➤ Sign Up
Actavis Labs Ut Inc LOXITANE loxapine succinate CAPSULE;ORAL 017525-004 Approved Prior to Jan 1, 1982 3,546,226 ➤ Sign Up
Actavis Labs Ut Inc LOXITANE C loxapine hydrochloride CONCENTRATE;ORAL 017658-001 Approved Prior to Jan 1, 1982 4,049,809 ➤ Sign Up
Actavis Labs Ut Inc LOXITANE loxapine succinate CAPSULE;ORAL 017525-003 Approved Prior to Jan 1, 1982 3,546,226 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for ACTAVIS LABS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2015-06-03
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Healthtrust
Express Scripts
Merck
Queensland Health
Chinese Patent Office
Johnson and Johnson
Harvard Business School
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.